Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Eledon Pharmaceuticals Q3 2026 Results: Net Loss of $3.93M, Loss Narrows

For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.9-17.5
EPS (diluted, $ a share)$-0.03$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ELDN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Eledon Pharmaceuticals, Inc.: key numbers

Share price
$1.97Close, Nov 16
Market cap
$166M
Shares outstanding
84.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Eledon Pharmaceuticals, Inc.

All →
4:11 PM ET 8-K
Financial Results

Eledon Pharmaceuticals Financial Results

Eledon Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $69.7 million and progress in its tegoprubart clinical program. The company remains on track to initiate its global Phase 3 LEGACY trial in kidney transplantation in Q4 2026 and recently received FDA Fast Track designation for the candidate.

Term
Q3 2026

“We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end.”

David-Alexandre C. Gros, M.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.